Payment overview · 2025
General Payments
$3,028.20
153 reported records · 26 companies
Healthcare provider profile · identity verified
James C Campau, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BAY CITY, MI · NPI 1932147758
Verified facts
What the public records show
CMS Open Payments records show James C Campau, D.O. received $3,028.20 in general payments during 2025 across 153 reported records.
Lilly USA, LLC accounted for 11.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta, Veozah.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $353.02 | 11.7% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $345.19 | 11.4% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $309.22 | 10.2% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $295.80 | 9.8% | 9 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $219.52 | 7.2% | 9 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $215.18 | 7.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $160.14 | 5.3% | 22 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $135.80 | 4.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $123.65 | 4.1% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $108.85 | 3.6% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $86.13 | 2.8% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $82.09 | 2.7% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $82.08 | 2.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $73.26 | 2.4% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $57.04 | 1.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.95 | 1.7% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $50.25 | 1.7% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $47.18 | 1.6% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.87 | 1.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.06 | 1.3% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $36.15 | 1.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.45 | 1.1% | 2 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $30.00 | 1.0% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $19.63 | 0.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.21 | 0.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.48 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,028.20 | 153 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $252.00 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $230.55 | 10 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $219.52 | 9 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $215.18 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $199.24 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $167.39 | 10 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $167.39 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $159.66 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $155.44 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $143.52 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $141.33 | 20 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $140.07 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $135.80 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $95.91 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $92.86 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.77 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.94 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $84.94 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $82.09 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $82.08 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $78.67 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $70.59 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $57.04 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $57.04 | 3 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $57.04 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.39 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.39 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.37 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $50.25 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.22 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $47.18 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.87 | 2 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $41.29 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $36.15 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $36.15 | 2 | 2025 |
Source payment records
|
|||||
| Kyleena Normalized: kyleena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.76 | 2 | 2025 |
Source payment records
|
|||||
| Mirena Normalized: mirena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.76 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.87 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.81 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 164 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 126 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 45 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
164 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
45 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
164 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 165 |
| Lisinopril | Lisinopril | 369 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 300 | 79 |
| Simvastatin | Simvastatin | 277 | 81 |
| Losartan Potassium | Losartan Potassium | 253 | 76 |
| Omeprazole | Omeprazole | 251 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 69 |
| Metformin Hcl | Metformin Hcl | 231 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 45 |
| Eliquis | Apixaban | 164 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 48 |
| Furosemide | Furosemide | 129 | 43 |
| Ozempic | Semaglutide | 126 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 35 |
| Xarelto | Rivaroxaban | 118 | 22 |
| Atenolol | Atenolol | 116 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 29 |
| Meloxicam | Meloxicam | 113 | 30 |
| Sertraline Hcl | Sertraline Hcl | 110 | 28 |
| Potassium Chloride | Potassium Chloride | 107 | 35 |
| Gabapentin | Gabapentin | 105 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 28 |
| Carvedilol | Carvedilol | 97 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 26 |
| Glipizide | Glipizide | 92 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 18 |
| Tramadol Hcl | Tramadol Hcl | 76 | 15 |
| Trazodone Hcl | Trazodone Hcl | 76 | 18 |
| Allopurinol | Allopurinol | 75 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 20 |
| Alprazolam | Alprazolam | 70 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 20 |
| Famotidine | Famotidine | 61 | 20 |
| Propranolol Hcl Er | Propranolol Hcl | 61 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 11 |
| Donepezil Hcl | Donepezil Hcl | 59 | 14 |
| Celecoxib | Celecoxib | 56 | 15 |
| Farxiga | Dapagliflozin Propanediol | 56 | 16 |
| Mounjaro | Tirzepatide | 55 | 12 |
| Mirtazapine | Mirtazapine | 52 | 12 |
| Montelukast Sodium | Montelukast Sodium | 48 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 13 |
| Finasteride | Finasteride | 46 | 13 |
| Jardiance | Empagliflozin | 46 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 45 | 36 |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 44 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 43 | 11 |
| Ibuprofen | Ibuprofen | 42 | 15 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Nystatin | Nystatin | 38 | 24 |
| Amoxicillin | Amoxicillin | 36 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 12 |
| Topiramate | Topiramate | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 26 |
| Spironolactone | Spironolactone | 27 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Prednisone | Prednisone | 21 | 12 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Niacin Er | Niacin | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Fluconazole | Fluconazole | 18 | 12 |
| Naproxen | Naproxen | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,028.20 · 153 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, CAPVAXIVE, COMIRNATY, DUROLANE, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, KISUNLA, Kerendia, Korlym, Kyleena, LEQVIO, M-M-R II, MOUNJARO, Mirena, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, PROQUAD, QULIPTA, REPATHA, REXULTI, ROTATEQ, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Tymlos, UBRELVY, VAXELIS, VAXNEUVANCE, VRAYLAR, VYEPTI, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error